Novo Nordisk Receives EU Approval for Hemophilia A Drug Frehemgo
Novo Nordisk announced on 13 November 2026 that the European Commission had granted marketing authorization for FREHEMGO (denecimig) as routine prophylaxis for adults and children with hemophilia A, with or without inhibitors. The company plans to launch the treatment in its first European markets in the year ahead. The authorization covers congenital factor VIII deficiency and is intended to prevent or reduce the frequency of bleeding episodes. Patients and healthcare teams can choose…